Sandbox:P.L: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 31: | Line 31: | ||
|} | |} | ||
*Median interval of [[transplantation]] - 4 years. (range .25-30.1) Fatality rate: 17.4% (4/23). | *Median interval of [[transplantation]] - 4 years. (range .25-30.1) Fatality rate: 17.4% (4/23). | ||
* Renal transplant [[patients]] of all ages groups are at a higher risk of [[COVID-19]] due to immunosuppression may develop [[COVID-19]]. | * Renal transplant [[patients]] of all ages groups are at a higher risk of [[COVID-19]] due to immunosuppression may develop [[COVID-19]]. | ||
* The youngest renal transplant patient who died of [[COVID-19]] according to analysis of 14 studies was 71 years old.<ref name="WellsPacini2013">{{cite journal|last1=Wells|first1=Samuel A.|last2=Pacini|first2=Furio|last3=Robinson|first3=Bruce G.|last4=Santoro|first4=Massimo|title=Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update|journal=The Journal of Clinical Endocrinology & Metabolism|volume=98|issue=8|year=2013|pages=3149–3164|issn=0021-972X|doi=10.1210/jc.2013-1204}}</ref> | |||
<references /> | |||
* The youngest renal transplant patient who died of [[COVID-19]] according to analysis of 14 studies was 71 years old | |||
Latest revision as of 18:33, 20 July 2020
- Median interval of transplantation - 4 years. (range .25-30.1) Fatality rate: 17.4% (4/23).
- Renal transplant patients of all ages groups are at a higher risk of COVID-19 due to immunosuppression may develop COVID-19.
- The youngest renal transplant patient who died of COVID-19 according to analysis of 14 studies was 71 years old.[1]
- ↑ Wells, Samuel A.; Pacini, Furio; Robinson, Bruce G.; Santoro, Massimo (2013). "Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update". The Journal of Clinical Endocrinology & Metabolism. 98 (8): 3149–3164. doi:10.1210/jc.2013-1204. ISSN 0021-972X.